We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

24 hedge funds and large institutions have $4.81M invested in AYTU BioPharma in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.1% less ownership

Funds ownership: 34.4% → 33.31% (-1.1%)

11% less funds holding

Funds holding: 27 → 24 (-3)

20% less capital invested

Capital invested by funds: $5.99M → $4.81M (-$1.18M)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
24
Holders Change
-3
Holders Change %
-11.11%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$73.8K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$23.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.55K
4
Bank of America
Bank of America
North Carolina
+$16

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$63.5K
2
AC
Armistice Capital
New York
-$41.4K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$10K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$4.45K
5
TRCT
Tower Research Capital (TRC)
New York
-$1.27K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$2.55M – – –
SCM
2
Stonepine Capital Management
Oregon
$1.18M +$73.8K +28,489 +6%
AC
3
Armistice Capital
New York
$555K -$41.4K -16,000 -6%
Renaissance Technologies
4
Renaissance Technologies
New York
$176K +$1.55K +600 +0.8%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$106K +$23.8K +9,183 +26%
Vanguard Group
6
Vanguard Group
Pennsylvania
$65.5K – – –
BlackRock
7
BlackRock
New York
$53.6K – – –
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$51.3K -$4.45K -1,719 -7%
Northern Trust
9
Northern Trust
Illinois
$34.2K – – –
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$34K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$3.46K -$1.27K -489 -25%
JP Morgan Chase
12
JP Morgan Chase
New York
$736 -$588 -227 -42%
Osaic Holdings
13
Osaic Holdings
Arizona
$705 – – –
Morgan Stanley
14
Morgan Stanley
New York
$681 -$389 -150 -34%
UBS Group
15
UBS Group
Switzerland
$611 -$124 -48 -16%
Wells Fargo
16
Wells Fargo
California
$291 – – –
Bank of America
17
Bank of America
North Carolina
$231 +$16 +6 +7%
CIBC Private Wealth Group
18
CIBC Private Wealth Group
Georgia
$195 – – –
Group One Trading
19
Group One Trading
Illinois
$87 – – –
NA
20
NewEdge Advisors
Louisiana
$49 – – –
CWM
21
CarsonAllaria Wealth Management
Illinois
$12 – – –
SIC
22
SJS Investment Consulting
Ohio
$12 – – –
US Bancorp
23
US Bancorp
Minnesota
$7 -$16 -6 -67%
Citadel Advisors
24
Citadel Advisors
Florida
– -$63.5K -21,810 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– -$10K -3,285 Closed
1
2

AYTU Hedge Fund Activity: Q3 2024 in Review

24 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2024, worth a combined $4.81M — down 20% from $5.99M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of AYTU and 0 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was Stonepine Capital Management, adding an estimated $73.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $63.5K sold.

  • 24 institutional investors held AYTU BioPharma (AYTU) as of Q3 2024, down from 27 in Q2 2024.
  • Funds reported $4.81M of AYTU BioPharma stock for Q3 2024, down 20% quarter-over-quarter.
  • 0 funds opened new AYTU BioPharma positions in Q3 2024 and 3 closed out, a net change of -3 holders.
  • The largest AYTU BioPharma buyer in Q3 2024 was Stonepine Capital Management, an estimated $73.8K added.
  • The largest AYTU BioPharma seller in Q3 2024 was Citadel Advisors, an estimated $63.5K sold.

Based on aggregated 13F filings for Q3 2024.